Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of elexacaftor/tezacaftor/ivacaftor in children aged 6 to 11 years with cystic fibrosis and F508del/minimal function genotype
MOH_2020-09-23_009341Phase 3Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in cystic fibrosis (CF) comparing elexacaftor/tezacaftor/ivacaftor morning + ivacaftor evening with matching placebo morning + matching placebo evening (2 arms). Started May 2020; status: active, not recruiting.
02
Drugs
elexacaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on MOH_2020-09-23_009341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-09-23_009341.